The global liquid biopsy market has been estimated at USD 418.5 in 2016 and is projected to reach USD 2,112.3 million by 2024,at a CAGR of 22.5% during forecast
PUNE, MAHARASHTRA, INDIA, November 16, 2016 /EINPresswire.com/ — The global liquid biopsy market has been estimated at USD 418.5 in 2016 and is projected to reach USD 2,112.3 million by 2024, at a CAGR of 22.5% during the forecast period from 2016 to 2024.
Global Liquid Biopsy Market by Sample Type (Blood, Urine and Others), by Biomarker Type (CTC, Ctdna and Others), By Application (Lung Cancer, GIT Cancer, Breast, Colorectal, Lukemia, Prostate and Others), By End User Type (Hospitals, Academic Institutes, Diagnostic Labs and Cancer Research Centers) and by Region (North America, Latin America, Europe, APAC and MEA) – Size, Share, Growth, Trends, and Forecasts (2016–2024)
Request For Sample of Report Here: https://market.biz/report/global-liquid-biopsy-market-uc/22379/#inquiry
Major drivers in the global liquid biopsy market are increasing prevalence of various cancers such as lung cancer, breast cancer, GIT cancers and prostate cancers and rising accessibility of advanced diagnosis procedures. These factors are expected to drive growth of the global liquid biopsy market during the forecast period. Other prominent driving factors are increasing oncologists preference towards liquid biopsy procedure for detecting cancer and increasing number of biotechnology and pharmaceutical companies research and developments to discover anti-cancer drugs. In addition to this, increasing regulatory bodies’ approvals for various new non-invasive tests is also driving growth of global liquid biopsy market. However, high cost, reimbursement scenario and awareness are the major restraining factors are expecting to hamper global liquid biopsy market over the forecast period.
By sample type, the global liquid biopsy market has been segment into blood, urine, and others (saliva, plasma, Cerebrospinal fluid (CSF)).
By marker type, the global liquid biopsy market has been segment into circulating tumour Cells (CTCs), circulating tumour nucleic acids (ctNA), and exosomes.
By disease indication, the global liquid biopsy market has been segmented into lung cancer, gastrointestinal cancer (GIT), breast cancer, colorectal, prostate cancer, leukemia and others. In terms of value, Lung cancer disease indication segment is currently accounts for utmost revenue as compared to other disease indication segments in the global liquid biopsy market. While breast cancer and colorectal cancers disease indication segments are anticipated to contribute significant revenue in global liquid biopsy market by the end of 2024.
Purchase Complete Report Here to get Instant access: https://market.biz/report/global-liquid-biopsy-market-uc/22379/
By end user, the global liquid biopsy market has been segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. In terms of value, Cancer institute end user segment is expected to make significant incremental opportunity in global liquid biopsy market over the forecast period.
The global liquid biopsy market has been segmented into five major regions: North America, Latin America, Europe, Europe, APAC, and Middle East & Africa (MEA). In 2016, North America is expected to account for the largest share and is expected to register a CAGR of 20.9% over the forecast period. This is owing to high adoption of novel advanced diagnostic technologies as well as increasing cancer prevalence in the U.S. and Canada. In terms of value, APAC region is estimated to be the fastest growing market and is expected to register a CAGR of 24.3% over the forecast period. By disease indication segment, Lung cancer disease segment in the APAC liquid biopsy market is expected to register a CAGR of 21.8% over the forecast period, owing to increasing lung cancer prevalence in this region.
Major players in the global liquid biopsy market are BIOCEPT, INC., F. Hoffmann-La Roche Ltd., Qiagen N.V., Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., Silicon Biosystems, Sysmex Corporation, Trovagene, and Pathway Genomics Corporation.
email us here
Source: EIN Presswire